Minghao Xu

4PUBLICATIONS
24CO-AUTHORS
Molecular targetsPredictive and prognostic markersInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 02, 2025
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC.

Bu-Gang Liang, Yi-Min Zheng, Ming-Hao Xu

|Oct 28, 2024
The Prognostic Significance of CTSV Expression in Patients with Hepatocellular Carcinoma.

Yuping He, Minghao Xu, Chenhao Zhou

|Mar 14, 2024
Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy.

Jialei Weng, Zheng Wang, Zhiqiu Hu

|Feb 15, 2023
Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.

Ming-Hao Xu, Cheng Huang, Mei-Ling Li

Pageof 1

Frequent Collaborators

2 joint publications

Ying-Hao Shen

1 joint publications

Jian Zhou

1 joint publications

Jia Fan

1 joint publications

Hui-Chuan Sun